Analysts Set Organogenesis Holdings Inc (NASDAQ:ORGO) Target Price at $10.75
Organogenesis Holdings Inc (NASDAQ:ORGO) has been given a consensus recommendation of “Buy” by the six ratings firms that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $10.75.
A number of research firms have recently issued reports on ORGO. Credit Suisse Group began coverage on shares of Organogenesis in a report on Monday, August 26th. They issued an “outperform” rating on the stock. Zacks Investment Research upgraded shares of Organogenesis from a “hold” rating to a “buy” rating and set a $8.75 price objective on the stock in a report on Saturday. Finally, BTIG Research set a $12.00 price objective on shares of Organogenesis and gave the company a “buy” rating in a report on Friday, August 9th.
In other news, major shareholder Michael W. Katz bought 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The stock was acquired at an average cost of $4.50 per share, with a total value of $45,000.00. Following the completion of the purchase, the insider now owns 10,000 shares of the company’s stock, valued at $45,000. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Avista Capital Managing Member bought 860,900 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was purchased at an average cost of $5.99 per share, with a total value of $5,156,791.00. Insiders purchased 1,521,603 shares of company stock valued at $8,499,019 over the last three months. 70.40% of the stock is owned by company insiders.
Shares of NASDAQ ORGO traded up $0.32 during midday trading on Friday, reaching $8.11. The company’s stock had a trading volume of 303 shares, compared to its average volume of 19,490. The company has a debt-to-equity ratio of 7.65, a current ratio of 1.43 and a quick ratio of 1.07. Organogenesis has a fifty-two week low of $3.56 and a fifty-two week high of $310.90. The stock has a 50 day simple moving average of $7.29 and a 200-day simple moving average of $6.48.
Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.01. The business had revenue of $64.27 million during the quarter, compared to analyst estimates of $64.00 million. Equities research analysts anticipate that Organogenesis will post -0.49 earnings per share for the current fiscal year.
Organogenesis Company Profile
Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.
See Also: Support Level
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.